Profile data is unavailable for this security.
About the company
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.
- Revenue in CNY (TTM)473.06m
- Net income in CNY101.38m
- Incorporated2004
- Employees508.00
- LocationCabio Biotech Wuhan Co LtdWuhan Medical Industry ParkJiangxia Avenue, Jiangxia DistrictWUHAN 430075ChinaCHN
- Phone+86 2 767845289
- Fax+86 2 765520985
- Websitehttp://www.cabio.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frontier Biotechnologies Inc | 126.99m | -308.96m | 2.21bn | 395.00 | -- | 1.72 | -- | 17.40 | -0.8248 | -0.8248 | 0.339 | 3.44 | 0.0575 | 1.40 | 3.00 | 321,484.60 | -13.99 | -14.05 | -16.25 | -15.78 | 30.10 | 2.35 | -243.30 | -450.08 | 2.86 | -- | 0.2347 | -- | 34.82 | 126.63 | 7.79 | -- | 28.13 | -- |
| Ginwa Enterprise Group Inc | 572.93m | -23.61m | 2.28bn | 553.00 | -- | 1.41 | -- | 3.97 | -0.0633 | -0.0633 | 1.53 | 4.32 | 0.2988 | 4.74 | 5.64 | 1,036,046.00 | -1.23 | 0.3641 | -1.44 | 0.4141 | 75.60 | 73.64 | -4.12 | 1.15 | 3.33 | 0.3439 | 0.0206 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
| Xinjiang Bai Hua Cun Pharma Tech Co Ltd | 384.44m | 26.95m | 2.28bn | 787.00 | 84.49 | 3.13 | -- | 5.94 | 0.0708 | 0.0708 | 1.01 | 1.91 | 0.367 | 1.38 | 1.79 | 488,492.20 | 2.57 | -4.59 | 3.60 | -6.24 | 48.38 | 24.09 | 7.01 | -18.40 | 1.44 | -- | 0.0021 | -- | 5.54 | -2.50 | 137.33 | -- | -21.00 | -- |
| Cabio Biotech Wuhan Co Ltd | 473.06m | 101.38m | 2.28bn | 508.00 | 22.70 | 1.52 | -- | 4.83 | 0.5977 | 0.5977 | 2.79 | 8.92 | 0.2948 | 2.49 | 2.27 | 931,222.90 | 6.01 | 7.81 | 6.55 | 8.34 | 41.34 | 46.96 | 20.40 | 28.65 | 6.19 | -- | 0.008 | 39.86 | 2.39 | 9.18 | 41.95 | -1.19 | 89.01 | -- |
| Novoprotein Scientific Inc | 136.28m | -927.60k | 2.29bn | 579.00 | -- | 1.05 | -- | 16.83 | -0.0132 | -0.0132 | 1.94 | 31.19 | 0.0585 | 0.4493 | 1.67 | 235,364.30 | -0.0398 | -- | -0.0409 | -- | 70.17 | -- | -0.6807 | -- | 34.49 | -- | 0.0353 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Beijing Succeeder Technology Inc | 284.54m | 120.76m | 2.30bn | 296.00 | 19.06 | 1.41 | -- | 8.09 | 1.14 | 1.14 | 2.68 | 15.36 | 0.1711 | 2.39 | 9.52 | 961,290.60 | 7.26 | 7.77 | 7.63 | 8.25 | 62.48 | 61.03 | 42.43 | 38.34 | 14.58 | -- | 0.00007 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Holder | Shares | % Held |
|---|---|---|
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 2.90m | 1.72% |
| Huashang Fund Management Co., Ltd.as of 31 Dec 2023 | 2.70m | 1.60% |
| UBS Asset Management Switzerland AGas of 24 Nov 2022 | 1.47m | 0.87% |
| Zhong Ou Asset Management Co., Ltdas of 30 Sep 2022 | 1.40m | 0.83% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 1.24m | 0.74% |
| Shenwan Hongyuan Securities Co., Ltd. (Invt Mgmt)as of 24 Nov 2022 | 840.00k | 0.50% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 551.05k | 0.33% |
| Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023 | 444.09k | 0.26% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 393.14k | 0.23% |
| Taikang Asset Management Co. Ltd.as of 24 Nov 2022 | 350.00k | 0.21% |
